2. Protein Tyrosine Kinase/RTK Immunology/Inflammation
  3. c-Fms TAM Receptor MHC
  4. Adrixetinib

Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.

For research use only. We do not sell to patients.

Adrixetinib

Adrixetinib Chemical Structure

CAS No. : 2394874-66-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of Adrixetinib:

Adrixetinib Related Antibodies

Top Publications Citing Use of Products

View All TAM Receptor Isoform Specific Products:

View All Isoforms
Axl Mer Tyro3

View All MHC Isoform Specific Products:

View All Isoforms
MHC I MHC II

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma[1][2].

IC50 & Target[1]

Axl

0.3 nM (Kd)

Mer

0.8 nM (Kd)

MHC I

 

In Vitro

Adrixetinib (Q702) (1 h) potently binds to and inhibits purified Axl, Mer, and CSF1R kinases with IC50 values of 0.3 nM, 0.8 nM, and 8.7 nM, respectively[1].
Adrixetinib (0.001-10 μM; 24 h pretreatment) concentration-dependently inhibits Gas6-induced phosphorylation of Axl and AKT in H1299 cells, concentration-dependently inhibits Gas6-induced phosphorylation of Mer and AKT in A549 cells, and concentration-dependently inhibits CSF1-induced phosphorylation of CSF1R and ERK in THP-1 cells[1].
Adrixetinib (0.1-100 μM; 72 h) directly inhibits EMT6 cell viability with an IC50 of 8.4 μM[1].
Adrixetinib inhibits M-NFS-60 cell proliferation through the CSF1R pathway with an IC50 < 1.0 μM, showing potent cellular activity[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Adrixetinib Related Antibodies

Western Blot Analysis[1]

Cell Line: H1299 cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 24 h (pretreatment); 1 h (Gas6 stimulation)
Result: Inhibited Gas6-induced phosphorylation of Axl (Tyr702) and AKT (Ser473) in a concentration-dependent manner.

Western Blot Analysis[1]

Cell Line: A549 cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: pretreatment; 1 h (Gas6 stimulation)
Result: Inhibited Gas6-induced phosphorylation of Mer (Tyr749/Tyr753/Tyr754) and AKT (Ser473) in a concentration-dependent manner.

Western Blot Analysis[1]

Cell Line: THP-1 cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 24 h (pretreatment); 5 min (CSF1 stimulation)
Result: Inhibited CSF1-induced phosphorylation of CSF1R (Tyr723) and ERK (Thr202/Tyr204) in a concentration-dependent manner.

Cell Viability Assay[1]

Cell Line: EMT6 mouse triple-negative breast cancer cells
Concentration: 0.1, 1, 10, 100 μM
Incubation Time: 72 h
Result: Exhibited direct cytotoxicity against EMT6 cells with an IC50 of 8.4 μM.
In Vivo

Adrixetinib (Q702) (30 mg/kg; p.o.; daily; 7 days) inhibits Axl and CSF1R phosphorylation in subcutaneous xenograft tumors in nude mice[1].
Adrixetinib (10-100 mg/kg; p.o.; daily; 14 days) induces dose-dependent tumor growth control (54.3% to 84.6%) in subcutaneous EMT6 syngeneic breast cancer tumors in BALB/c mice[1].
Adrixetinib (30 mg/kg; p.o.; daily; up to 7 days) modulates EMT6 gene expression in subcutaneous EMT6 tumors to promote an immune-stimulatory microenvironment in BALB/c mice[1].
Adrixetinib (30 mg/kg; p.o.; daily; 5 to 22 days) remodels the immune cell population in subcutaneous MHC-I and E-cadherin expression in BALB/c mice[1].
Adrixetinib (30 mg/kg; p.o.; daily; 7 days) enhances the effector function of T and natural killer cells by increasing IFN-γ and granzyme B production in both subcutaneous EMT6 tumors and peripheral blood of BALB/c mice[1].
Adrixetinib (30 mg/kg; p.o.; daily; 21 days) increases CD8 T cell infiltration, reduces myeloid cell accumulation, and upregulates MHC-I and PD-L1 expression in subcutaneous EMT6 tumors in BALB/c mice[1].
Adrixetinib (30 mg/kg; p.o.; daily; 9 days) increases tumor antigen-specific CD8 T cell infiltration into subcutaneous B16F10-OVA melanoma tumors in C57BL/6 mice[1].
Adrixetinib (30 mg/kg; p.o.; daily; up to 27 days) induces tumor growth inhibition (64% to 77% TGI) in subcutaneous CT26, MC38, and RENCA syngeneic tumor models in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female, 6-8 weeks old, subcutaneously implanted with H1299 human non-small cell lung carcinoma cells or M-NFS-60 murine myeloid leukemia cells mixed with Matrigel)[1]
Dosage: 30 mg/kg
Administration: p.o.; daily; 7 days
Result: Inhibited phosphorylation of Axl in H1299 tumor samples.
Inhibited phosphorylation of CSF1R in M-NFS-60 tumor samples.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)[1]
Dosage: 10 mg/kg; 30 mg/kg; 100 mg/kg
Administration: p.o.; daily; 14 days
Result: Achieved 54.3%, 64.9%, and 84.6% tumor growth control, respectively, and significantly reduces tumor volume compared with the control group.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)[1]
Dosage: 30 mg/kg
Administration: p.o.; daily; up to 7 days
Result: Upregulated CD8⁺ T cell, natural killer cell and MHC‑I signature genes in a time‑dependent manner.
Downregulated tumor‑associated macrophage and myeloid‑derived suppressor cell signature genes in a time‑dependent manner.
Validated enhanced immune‑activating signatures and diminished immunosuppressive signatures by day 7 using gene expression heatmaps.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)[1]
Dosage: 30 mg/kg
Administration: p.o.; daily; 5 or 22 days
Result: Reduced tumor volume significantly compared with controls by day 22.
Decreased the proportion of tumor-infiltrating M-MDSCs by 2.3-fold and repolarized tumor-associated macrophages toward the M1 phenotype while reducing M2 populations, with these immune alterations sustained through day 22.
Elevated CD8⁺ T cell proportions at both days 5 and 22, and preserved higher MHC-I and increased E-cadherin protein expression in tumors by day 22.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)[1]
Dosage: 30 mg/kg
Administration: p.o.; daily; 7 days
Result: Significantly increased proportion of IFN-γ-producing CD4 T cells and granzyme B+ CD8 T cells in tumor samples relative to controls.
Significantly increased proportion of IFN-γ-producing CD4 T and natural killer cells, and granzyme B+ CD8 T cells in peripheral blood relative to controls.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)[1]
Dosage: 30 mg/kg
Administration: p.o.; daily; 21 days
Result: Increased tumor-infiltrating CD8 T cell percentages relative to controls.
Decreased myeloid cell percentages relative to controls.
Increased MHC-I and PD-L1 protein expression in CD45-negative tumor cells relative to controls.
Animal Model: C57BL/6 (female, 7-8 weeks old, subcutaneously implanted with B16F10-OVA murine melanoma cells)[1]
Dosage: 30 mg/kg
Administration: p.o.; daily; 9 days
Result: Induced partial tumor growth inhibition.
Significantly increased percentage of OVA-specific CD8 T cells (detected via SIINFEKL-H-2Kb tetramer staining) in tumor samples relative to controls.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with RENCA murine renal adenocarcinoma cells or CT26 murine colon carcinoma cells); C57BL/6 (female, 6-8 weeks old, subcutaneously implanted with MC38 murine colon adenocarcinoma cells)[1]
Dosage: 30 mg/kg
Administration: p.o.; daily; up to 27 days
Result: Achieved 77% tumor growth control in CT26 colon tumors by day 27.
Achieved 64% tumor growth control in MC38 colon tumors by day 27.
Reduced tumor volume in RENCA renal tumors relative to controls.
Molecular Weight

531.48

Formula

C25H24F3N5O5
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=NN(CCC)C=C1OCC(F)(F)F)NC2=NC=C(C=C2)OC3=C4C=C(OC)C(OC)=CC4=NC=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (188.15 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8815 mL 9.4077 mL 18.8154 mL
5 mM 0.3763 mL 1.8815 mL 3.7631 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8815 mL 9.4077 mL 18.8154 mL 47.0385 mL
5 mM 0.3763 mL 1.8815 mL 3.7631 mL 9.4077 mL
10 mM 0.1882 mL 0.9408 mL 1.8815 mL 4.7038 mL
15 mM 0.1254 mL 0.6272 mL 1.2544 mL 3.1359 mL
20 mM 0.0941 mL 0.4704 mL 0.9408 mL 2.3519 mL
25 mM 0.0753 mL 0.3763 mL 0.7526 mL 1.8815 mL
30 mM 0.0627 mL 0.3136 mL 0.6272 mL 1.5679 mL
40 mM 0.0470 mL 0.2352 mL 0.4704 mL 1.1760 mL
50 mM 0.0376 mL 0.1882 mL 0.3763 mL 0.9408 mL
60 mM 0.0314 mL 0.1568 mL 0.3136 mL 0.7840 mL
80 mM 0.0235 mL 0.1176 mL 0.2352 mL 0.5880 mL
100 mM 0.0188 mL 0.0941 mL 0.1882 mL 0.4704 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Adrixetinib Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Adrixetinib2394874-66-7Q702Q 702Q-702c-FmsTAM ReceptorMHCCSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RTyro3AxlMerMajor Histocompatibility Complexcolon carcinomarenal adenocarcinomaCD8 T cellM2 macrophagebreast cancerMDSCM1 macrophageInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Adrixetinib
Cat. No.:
HY-152830
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.